Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. Kobayashi K, et al. Among authors: suzuki d. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231222837. doi: 10.1177/14791641231222837. Diab Vasc Dis Res. 2023. PMID: 38096503 Free PMC article.
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, Furuki T, Chin K, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Degawa H, Hishiki T, Shimura H, Nakajima S, Miyauchi M, Yamamoto H, Hatori Y, Hayashi M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: suzuki d. Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec. Cardiovasc Endocrinol Metab. 2023. PMID: 37779602 Free PMC article.
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Tsukamoto S, Kobayashi K, Toyoda M, Hatori N, Kanaoka T, Wakui H, Sakai H, Furuki T, Chin K, Ito S, Suzuki D, Umezono T, Aoyama T, Nakajima S, Hishiki T, Hatori Y, Hayashi M, Shimura H, Minagawa F, Mokubo A, Takihata M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Tsukamoto S, et al. Among authors: suzuki d. Hypertens Res. 2024 Mar;47(3):628-638. doi: 10.1038/s41440-023-01464-y. Epub 2023 Oct 17. Hypertens Res. 2024. PMID: 37848562
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: suzuki d. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: suzuki d. Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38764356
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944. Diabetes Care. 2022. PMID: 35061867 Free PMC article. Clinical Trial.
Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
Ishii H, Kamei N, Shimono D, Niiya T, Tosaki T, Kitazawa T, Suzuki D, Wakasa Y, Seino H, Oishi M, Ohashi H, Higami K, Akai H; ONWARD-DPP4 study investigators. Ishii H, et al. Among authors: suzuki d. Diabetes Ther. 2023 Oct;14(10):1639-1658. doi: 10.1007/s13300-023-01442-0. Epub 2023 Jul 19. Diabetes Ther. 2023. PMID: 37468684 Free PMC article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Diabetes Care. 2023 Sep 1;46(9):1721. doi: 10.2337/dc23-er09. Diabetes Care. 2023. PMID: 37310695 Free PMC article. No abstract available.
A Focal Chronic Myopathic Form of Muscular Sarcoidosis.
Suzuki D, Uchimura F, Nishida A. Suzuki D, et al. Mayo Clin Proc. 2024 May 17:S0025-6196(24)00093-4. doi: 10.1016/j.mayocp.2024.02.009. Online ahead of print. Mayo Clin Proc. 2024. PMID: 38762816 No abstract available.
974 results